Roth Capital Brokers Increase Earnings Estimates for CLRB

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Roth Capital lifted their Q2 2025 earnings estimates for shares of Cellectar Biosciences in a research note issued on Tuesday, May 13th. Roth Capital analyst J. Aschoff now anticipates that the biopharmaceutical company will post earnings of ($0.13) per share for the quarter, up from their prior forecast of ($0.15). The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.59) per share. Roth Capital also issued estimates for Cellectar Biosciences’ Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.48) EPS, FY2027 earnings at ($0.46) EPS and FY2028 earnings at ($0.05) EPS.

Cellectar Biosciences (NASDAQ:CLRB) last posted its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.04.

Other equities research analysts have also recently issued research reports about the stock. Maxim Group restated a “hold” rating on shares of Cellectar Biosciences in a report on Wednesday. StockNews.com began coverage on shares of Cellectar Biosciences in a report on Tuesday. They issued a “sell” rating on the stock.

Cellectar Biosciences Price Performance

CLRB stock opened at $0.25 on Friday. Cellectar Biosciences has a 1 year low of $0.22 and a 1 year high of $3.42. The company has a market cap of $11.29 million, a P/E ratio of -0.14 and a beta of 0.48. The firm has a 50-day moving average of $0.29 and a 200 day moving average of $0.59.

Hedge Funds Weigh In On Cellectar Biosciences

Several hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd lifted its position in shares of Cellectar Biosciences by 122.6% in the 1st quarter. XTX Topco Ltd now owns 104,323 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 57,447 shares during the period. Simplex Trading LLC lifted its stake in shares of Cellectar Biosciences by 331.3% during the first quarter. Simplex Trading LLC now owns 173,129 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 132,986 shares during the period. Baader Bank Aktiengesellschaft acquired a new stake in shares of Cellectar Biosciences during the first quarter worth $55,000. JPMorgan Chase & Co. lifted its stake in shares of Cellectar Biosciences by 687.3% during the fourth quarter. JPMorgan Chase & Co. now owns 182,403 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 159,234 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of Cellectar Biosciences by 25.3% during the fourth quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 41,704 shares during the last quarter. 16.41% of the stock is currently owned by institutional investors.

About Cellectar Biosciences

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.